Prenetics Global (PRE) Projected to Post Earnings on Thursday

Key Points

• Prenetics Global is expected to report Q1 2026 results before the market opens on Thursday, May 14, with analysts forecasting ($0.66) EPS and $37.903 million in revenue; a conference call is scheduled for May 13 at 11:00 AM ET.
• The board has authorized a $40 million share buyback — representing up to 15.8% of shares — which typically signals management believes the stock is undervalued.
• Shares trade around $15.90 with a market cap of $267.6M and a 52‑week range of $5.07–$23.63; analysts carry a consensus "Moderate Buy" rating and a $32.33 target, though coverage is mixed (three buys, one sell) and institutions own about 25% of the stock.

Prenetics Global (NASDAQ:PRE - Get Free Report) will likely be issuing its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect the company to announce earnings of ($0.66) per share and revenue of $37.9030 million for the quarter. Parties may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 11:00 AM ET.

Prenetics Global (NASDAQ:PRE - Get Free Report) last issued its earnings results on Wednesday, February 18th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.22. The company had revenue of $36.60 million during the quarter, compared to the consensus estimate of $36.15 million. Prenetics Global had a negative return on equity of 19.61% and a negative net margin of 61.33%. On average, analysts expect Prenetics Global to post $-3 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Prenetics Global Stock Performance

Shares of NASDAQ:PRE opened at $15.90 on Thursday. The business's 50-day simple moving average is $18.73 and its 200 day simple moving average is $17.01. The company has a market cap of $267.57 million, a P/E ratio of -3.96 and a beta of 0.15. Prenetics Global has a one year low of $5.07 and a one year high of $23.63.

Prenetics Global announced that its board has authorized a share buyback plan on Friday, March 6th that permits the company to buyback $40.00 million in shares. This buyback authorization permits the company to repurchase up to 15.8% of its shares through open market purchases. Shares buyback plans are generally an indication that the company's management believes its shares are undervalued.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC bought a new position in Prenetics Global during the 4th quarter worth $1,302,000. Millennium Management LLC bought a new stake in Prenetics Global in the fourth quarter valued at $810,000. Marshall Wace LLP bought a new stake in Prenetics Global in the fourth quarter valued at $788,000. UBS Group AG boosted its holdings in shares of Prenetics Global by 581.9% during the third quarter. UBS Group AG now owns 46,561 shares of the company's stock valued at $619,000 after acquiring an additional 39,733 shares during the period. Finally, Goldman Sachs Group Inc. acquired a new position in shares of Prenetics Global during the fourth quarter valued at $665,000. Institutional investors and hedge funds own 25.01% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on PRE shares. Wall Street Zen lowered Prenetics Global from a "buy" rating to a "hold" rating in a research report on Monday, February 16th. Roth Mkm initiated coverage on shares of Prenetics Global in a research note on Wednesday, February 11th. They issued a "buy" rating and a $36.00 price target for the company. Lake Street Capital initiated coverage on shares of Prenetics Global in a report on Monday, March 16th. They issued a "buy" rating and a $29.00 price target on the stock. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Prenetics Global in a research note on Tuesday, April 21st. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Prenetics Global presently has a consensus rating of "Moderate Buy" and a consensus price target of $32.33.

Prenetics Global Company Profile

Prenetics Global NASDAQ: PRE is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company's core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.